Clinical trials: Bronchial Neoplasms
Lung Cancer, Small Cell, Solid Tumor Cancer
A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors
The purpose of this study is to compare two capsules of topotecan made by slightly different methods. This will be done by giving the drug made by the two different methods to patients orally and testing blood levels.
- Trial name
- NCT00046111
- Testing
- topotecan
- Where
- 5 sites in United States, Canada
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Cancer
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
This was a Phase II, multicenter, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib administered as a single agent and in combination with trametinib in stage IV disease to subjects…
- Trial name
- NCT01336634
- Testing
- Dabrafenib, Trametinib
- Where
- 50 sites in United States, France and 9 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Non Small Cell Lung Cancer
Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, & Adjuvant Chemo in Stage III NSCLC
This is a phase II study to evaluate the toxicity and overall survival of pulsed paclitaxel with concurrent thoracic radiotherapy, and adjuvant gemcitabine and carboplatin in stage IIIA and IIIB non-small cell lung cancer
- Trial name
- NCT00449657
- Testing
- Taxol (paclitaxel), Radiotherapy, Carboplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Leo W. Jenkins Cancer Center
Small-cell Lung Cancer
Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study
To compare the efficacy and safety between teniposide, cisplatin and serplulimab regimen and etoposide, cisplatin and serplulimab regimen in the treatment of extensive stage small lung cancer
- Trial name
- NCT07583511
- Testing
- Teniposide, Etoposide, serplulimab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sun Yat-sen University
Lung Cancer
Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer
Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00009971
- Testing
- fenretinide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
Utility of Anatometabolic Imaging for Radiation Treatment Planning for Lung Cancer
This is a research study for patients with inoperable lung cancer called non-small cell lung cancer (NSCLC). Currently, the information from a radiological test, computed tomography (CT) scan of the chest, is used to design the…
- Trial name
- NCT00005666
- Testing
- PET scan use in radiotherapy planning
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Small-cell Lung Cancer
Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC
This study is a prospective, single-arm, phase Ⅱ trial evaluating the safety and efficacy of Chemotherapy-immunotherapy-based split-course adaptive hypofractionated radiotherapy for extensive-stage SCLC
- Trial name
- CISART (NCT06816966)
- Testing
- split-course adaptive hypofractionated radiotherapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fujian Medical University Union Hospital
Breast Cancer, Lung Cancer
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer
RATIONALE: Vaccines made from the HER2/neu antigen may make the body build an immune response and kill tumor cells. Colony-stimulating factors such as GM-CSF increase the number of immune cells found in bone marrow or peripheral…
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00003002
- Testing
- HER-2/neu peptide vaccine, sargramostim
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
Lung Neoplasms, Quality of Life
Impact on Quality of Life From Multi-modality Lung Cancer
The investigators aim to explore how lung cancer patients and their family carers are affected by different types of cancer treatment. The investigators are focusing on a particular type of lung cancer called Stage III N2.
- Trial name
- PIONEER (NCT04540757)
- Testing
- Surgery, No surgery
- Where
- 2 sites in United Kingdom
- Volunteers
- 66 people
- Sponsor
- The Christie NHS Foundation Trust
Carcinoma, Small Cell Lung
Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
This is a Phase II, single arm, multicenter study designed to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) concurrent cisplatin/carboplatin plus etoposide with atezolizumab in participants who have…
- Trial name
- Match (NCT04622228)
- Testing
- Atezolizumab, Cisplatin, Carboplatin
- Where
- 8 sites in China
- Volunteers
- 56 people
- Sponsor
- Hoffmann-La Roche
Stage III Non-small-cell Lung Cancer
A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer
Stage III non-small-cell lung cancer (NSCLC) is seen in a relatively heterogeneous group of patients with ipsilateral mediastinal (N2) lymph node involvement. The relative roles of different treatment modalities are not clear.
- Trial name
- NCT04181372
- Testing
- Anlotinib hydrochloride, platinum-based chemotherapy medicine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Carcinoma, Non-Small-Cell Lung
OMEGA, Local Ablative Therapy in Oligometastatic NSCLC
Oligometastatic lung cancer (OM-NSCLC) seems to be associated with a better prognosis than usual Stage IV non-small cell lung cancer when radical local therapy of all metastatic sites is administered but the impact of such an…
- Trial name
- OMEGA (NCT03827577)
- Testing
- Surgical removal of primary and/or of all oligometastases, Non-surgical LAT, Standard medical therapy
- Where
- Italy
- Volunteers
- 195 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Lung Cancer
Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer That Can Be Removed by Surgery
RATIONALE: Palliative care may be more effective than standard care in improving quality of life and symptoms in patients with lung cancer.
- Trial name
- NCT00823667
- Testing
- educational intervention, medical chart review, questionnaire administration
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- City of Hope Medical Center
Renal Cell Carcinoma, Melanoma
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
In this study, the Phase Ib portion aims to establish safety and tolerability of ARRY-614 with either nivolumab or ipilimumab and to determine a recommended phase II dose of ARRY-614 in combination with either nivolumab or…
- Conditions
- Renal Cell Carcinoma, Melanoma, Solid Tumor, Non-small Cell Lung Cancer
- Trial name
- NCT04074967
- Testing
- Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Dan Zandberg
Carcinoma, Non-Small-Cell Lung, Bronchial Neoplasms
Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients
A multi-centre observational, non-interventional study is to dynamically monitor the changes of circulating tumor DNA (ctDNA) in late stage NSCLC patients under Gefitinib treatment.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases
- Trial name
- NCT02804100
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Wenzhou Medical University
Non-Small Cell Lung Cancer
Real-world Association Between Concomitant Beta-blocker Exposure and Anti-PD-1/PD-L1 Treatment Outcomes in Advanced Non-Small Cell Lung Cancer
This retrospective real-world cohort study evaluated whether concomitant long-term beta-blocker exposure during routine clinical care was associated with clinical outcomes in patients with advanced NSCLC who received standard…
- Trial name
- NCT05387512
- Testing
- Anti-PD-1/PD-L1 Therapy (Standard of Care), Beta-blocker (Concomitant Exposure)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Affiliated Hospital of Nantong University
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation
The Drugs Controller General of India (DCGI) has granted approval for Asciminib film-coated 40 mg tablets on 20 Oct 2023 with the condition to perform a Phase IV clinical study in Indian patients with Philadelphia…
- Trial name
- ASC4INDIA (NCT06427811)
- Testing
- Asciminib
- Where
- 10 sites in India
- Volunteers
- 85 people
- Sponsor
- Novartis Pharmaceuticals
Small-cell Lung Cancer
Bioinformation Therapy for Lung Cancer
The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable lung cancer.
- Trial name
- NCT03239171
- Testing
- Cancer ablation, Life information rehabilitation therapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.